Haw Par Corporation Ltd
SGX:H02
Haw Par Corporation Ltd
SGX:H02
Price:
15.58
SGD
3.32%
Market Cap:
S$3.4B
Relative Value
The Relative Value of one
H02
stock under the Base Case scenario is
hidden
SGD.
Compared to the current market price of 15.58 SGD,
Haw Par Corporation Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
H02 Relative Value
HIDDEN
Multiples Across Competitors
H02 Competitors Multiples
Haw Par Corporation Ltd Competitors
Haw Par Corporation Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SG |
|
Haw Par Corporation Ltd
SGX:H02
|
3.4B SGD | 15 | 13 | 35.6 | 38.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP | 5.1 | 29.3 | 16.2 | 22.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
